Key Points
- Oxford BioDynamics has appointed Richard Compton as chief executive to lead its next phase of development.
- The company reported interim revenues of £690,000 for the six months ending 31 March 2026, up 17 per cent year on year.
- Compton brings more than 25 years of life sciences leadership experience across genomics, diagnostics, scientific software and healthcare technology.
- He previously held senior roles at Oxford Nanopore Technologies, Illumina and the BIOVIA business unit of Dassault Systèmes.
- Oxford BioDynamics said Compton scaled businesses from early commercialisation to global adoption.
- Iain Ross, executive chairman since January 2025, will remain as non-executive chair.
- Ross said the board wanted a chief executive with deep experience in scaling genomics and diagnostics companies internationally.
- Compton said his immediate focus will be execution, customer adoption, clinical utility, strategic partnerships and disciplined resource allocation.
- Compton will be appointed to the board of Oxford BioDynamics in due course.
Oxford (Oxford Daily) June 30, 2026 – Oxford BioDynamics has appointed Richard Compton as its new chief executive as the Oxford-based biotech moves into what it describes as the next phase of its development. The company also reported interim revenues of £690,000 for the six months ending 31 March 2026, representing a 17 per cent increase on the same period a year earlier. The appointment places a senior commercial life sciences executive at the helm of a business seeking to strengthen its market position.
The company said Compton brings more than 25 years of operational, commercial and P&L leadership experience across genomics, diagnostics, scientific software and healthcare technology. His background includes senior leadership roles at Oxford Nanopore Technologies, Illumina and the BIOVIA business unit of Dassault Systèmes. Oxford BioDynamics said he has also scaled complex technology businesses from early commercialisation to global adoption.
What experience does Richard Compton bring?
Compton most recently served as senior vice president of sales and commercial operations at Oxford Nanopore Technologies until late 2025. He was part of the executive leadership team during the company’s transition into a publicly listed global genomics company. Oxford BioDynamics said that during his tenure, annual revenues at Oxford Nanopore grew from approximately £4 million to more than £200 million, and the company completed its London Stock Exchange initial public offering.
Before Oxford Nanopore, Compton was vice president and general manager for EMEA at Illumina. In that role, he led the business across more than 40 countries and held full P&L responsibility for a commercial operation that expanded from less than $280 million in 2012 to more than $600 million by 2015. Oxford BioDynamics said he oversaw the region during a period of rapid adoption of next-generation sequencing across research, clinical, translational and national genomics markets.
Why did the board make this move?
Iain Ross, who has served as executive chairman since January 2025, said he would remain as non-executive chair after the transition. Ross said his focus since joining the company had been on stabilising and refocusing the business, strengthening commercial foundations and preparing it for the next stage of development. He said the board believed Oxford BioDynamics now needed a chief executive with deep experience in scaling commercial genomics and diagnostics organisations internationally.
Ross said Compton “brings precisely that experience” and credited him with helping build and scale major life sciences technology businesses at Oxford Nanopore, Illumina and Accelrys. He said the appointment reflected confidence that Oxford BioDynamics has the scientific and clinical foundation to become a leading international diagnostics company, supported by its proprietary 3D genomics platform, commercially available precision clinical tests and strategic industry partnerships. Ross also thanked the management team and staff for their work, resilience and commitment over the past 18 months.
What did Richard Compton say?
Compton said he was delighted to join Oxford BioDynamics at an important point in its development. He described the company as having a distinctive scientific and clinical foundation, commercially available products, a proprietary 3D genomics technology platform and a growing body of clinical and translational evidence. He said the challenge now is to turn that foundation into a more focused, scalable and commercially disciplined business.
He said his immediate focus would be on execution, with priorities including clinical utility, customer adoption, strategic partnerships and disciplined allocation of resources towards the opportunities with the greatest potential to create value for patients, customers and shareholders. Compton also said he looked forward to working with Ross, the board, the wider OBD team and the company’s customers, partners and investors as it shapes the next phase of development.
What does the revenue update show?
The interim revenue figure of £690,000 suggests the business remains at a relatively early commercial stage, even though it is growing. The 17 per cent year-on-year rise indicates movement in the right direction, but the company still appears to be focused on building scale rather than delivering large-scale turnover. In that context, the choice of a chief executive with experience in commercial expansion appears aligned with the company’s stated objectives.
The revenue update also provides context for the leadership change. A business at this stage often needs a leader who can combine scientific credibility with commercial discipline and international market experience. Oxford BioDynamics appears to be positioning itself for that transition.
How does this fit the company’s strategy?
Oxford BioDynamics framed the appointment as part of its effort to build a leading international diagnostics company. The company highlighted its proprietary 3D genomics platform, commercially available precision clinical tests and strategic industry partnerships as the foundations for that ambition. The leadership change suggests the business wants to move beyond scientific capability and into broader commercial execution.
The board’s comments indicate a strong emphasis on scale, partnership development and focused allocation of resources. That suggests the company is trying to sharpen its business model while keeping the emphasis on clinical and scientific value. Compton’s background in public companies and large-scale genomics businesses fits that direction closely.
Background of the development
Oxford BioDynamics is a biotech company based in Oxford that develops clinical diagnostic tests. The business has been working through a period of stabilisation and refocusing under Iain Ross, who became executive chairman in January 2025. The appointment of a new chief executive now marks a further step in that process as the company seeks to strengthen commercial execution and prepare for growth.
The move also reflects a broader pattern across life sciences, where companies often appoint leaders with deep commercial experience when they are moving from product development into wider market adoption. In this case, Oxford BioDynamics is signalling that it wants a more international, commercially disciplined leadership structure. The combination of rising revenues, a new chief executive and a continuing non-executive chair arrangement suggests a deliberate transition rather than a sudden change of direction.
Prediction
For investors, the appointment may be seen as a sign that Oxford BioDynamics wants to prioritise revenue growth, operational discipline and strategic partnerships. If Compton applies the commercial playbook he used at Oxford Nanopore and Illumina, the company could become more focused on scaling adoption of its tests and platform. That would be particularly relevant for shareholders looking for clearer evidence of commercial traction.
For customers and partners, the change may lead to a more structured sales approach and a stronger emphasis on clinical utility. For employees, it may mean tighter priorities and a greater focus on execution. For the wider diagnostics market, the appointment suggests Oxford BioDynamics is aiming to compete more confidently as an international life sciences company.
